ArticleJournal of virology1994
Use of recombinant virus to assess human cytomegalovirus early and late promoters in the context of the viral genome.
Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Features and Functions of the Conserved Herpesvirus Tegument Protein UL11 and Its Binding Partners.Frontiers in microbiology · 2022Review
- Replication kinetics of turkey herpesvirus in lymphoid organs and feather follicle epithelium in chickens.The Journal of veterinary medical science · 2021Article
- The Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming a Complex with gH Independently from gL.Journal of virology · 2016Article
- Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.Journal of virology · 2014Article
- Heterologous viral promoters incorporated into the human cytomegalovirus genome are silenced during experimental latency.Journal of virology · 2013Article
- Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.Journal of virology · 2013Article
- The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope.Journal of virology · 2012Article
- The human cytomegalovirus gene products essential for late viral gene expression assemble into prereplication complexes before viral DNA replication.Journal of virology · 2011Article
- Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.Virology journal · 2011Article
- Functional properties of the human cytomegalovirus IE86 protein required for transcriptional regulation and virus replication.Journal of virology · 2010Article
- Murine gammaherpesvirus 68 open reading frame 24 is required for late gene expression after DNA replication.Journal of virology · 2007Article
- An acidic cluster of human cytomegalovirus UL99 tegument protein is required for trafficking and function.Journal of virology · 2004Article
- Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element.Journal of virology · 2000Article
- Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.Antimicrobial agents and chemotherapy · 2000Article
- Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis.Journal of virology · 1999Article
- Transcriptional regulation of the human cytomegalovirus US11 early gene.Journal of virology · 1999Article
- Separate DNA elements containing ATF/CREB and IE86 binding sites differentially regulate the human cytomegalovirus UL112-113 promoter at early and late times in the infection.Journal of virology · 1998Article
- Identification of positive and negative regulatory regions involved in regulating expression of the human cytomegalovirus UL94 late promoter: role of IE2-86 and cellular p53 in mediating negative regulatory function.Journal of virology · 1998Article
- Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle.Journal of virology · 1997Article
- The role of ATF in regulating the human cytomegalovirus DNA polymerase (UL54) promoter during viral infection.Journal of virology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We have developed a system to study human cytomegalovirus (HCMV) cis-acting promoter elements within the context of the viral genome. A recombinant HCMV (RV134) containing a marker gene (beta-glucuronidase) was used to insert HCMV promoter-chloramphenicol acetyltransferase gene constructs into the viral genome between open reading frames US9 and US10. Using this system, we have studied the promoters for the early DNA polymerase gene (UL54), the early-late lower matrix phosphoprotein gene (pp65, UL83), and the true late 28-kDa structural phosphoprotein gene (pp28, UL99). Transient-expression assays demonstrated that the pp65 and pp28 promoters are activated earlier and to higher levels than typically observed with the endogenous gene. In contrast, insertion of these promoters into the viral genome resulted in kinetics which mimicked that of the endogenous genes. In addition, we have also tested a variant of the pp28 promoter (d24/26CAT) which is deleted from -609 to -41. This promoter behaved similarly to the wild-type pp28 promoter, indicating that sequences from -40 to +106 are sufficient for conferring true late kinetics. Taken together, these data demonstrate that the viral genome affords a level of regulation on HCMV gene expression that has been previously unrealized. Therefore, these experiments provide a model system for the analysis of cis-acting promoter regulatory elements in the context of the viral genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.